약물유전체학 시장 규모, 점유율 및 성장 분석 : 제품 및 서비스별, 기술별, 검체 유형별, 용도별, 지역별, 업계 예측(2026-2033년)

Global Pharmacogenomics Market size was valued at USD 3.5 Billion in 2024 and is poised to grow from USD 3.87 Billion in 2025 to USD 8.6 Billion by 2033, growing at a CAGR of 10.5% during the forecast period (2026-2033).

The global pharmacogenomics market is experiencing robust growth, driven by the expansion of the pharmaceutical industry and the increasing demand for precision medicine that ensures enhanced drug safety. The rise in chronic lifestyle-related diseases is prompting healthcare providers to adopt targeted therapies that promise better efficacy and minimized side effects. Additionally, the application of pharmacogenomics in cancer treatment, including its role in predicting drug reactions, resistance, efficacy, and the toxicity of chemotherapeutic and targeted immunotherapy agents, further propels market growth. This trend reflects a shift toward personalized medicine, where genetic insights significantly influence treatment decisions, ultimately supporting the ongoing development and investment in pharmacogenomic solutions.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pharmacogenomics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pharmacogenomics Market Segments Analysis

The global pharmacogenomics market is segmented into product & service, technology, sample type, application, and region. By product & service, the market is divided into instruments, reagents & kits, and software & services. Depending on technology, it is classified into polymerase chain reaction (PCR), DNA sequencing, microarray, mass spectrometry, and electrophoresis. According to sample type, the market is bifurcated into blood and saliva. As per the application, it is categorized into drug discovery & development, oncology, neurology, cardiology, and pain management. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.

Driver of the Global Pharmacogenomics Market

One of the key market drivers for the global pharmacogenomics market is the increasing demand for personalized medicine. As healthcare shifts towards tailored treatment approaches, pharmacogenomics plays a crucial role in providing insights into how an individual's genetic makeup affects their response to specific medications. This shift is fueled by advancements in genomic technologies, which allow for more efficient and accurate genomic profiling, enabling healthcare providers to optimize drug selection and dosing. Furthermore, the growing prevalence of chronic diseases and the need for more effective therapeutic solutions are propelling investments in pharmacogenomic research and development, thereby driving market growth.

Restraints in the Global Pharmacogenomics Market

One significant market restraint for the global pharmacogenomics market is the high cost and complexity of genetic testing. The development and implementation of pharmacogenomic tests often require advanced technologies and specialized laboratory infrastructure, leading to elevated costs that can hinder widespread adoption, particularly in developing regions. Furthermore, the interpretation of genetic data necessitates expertise and can be time-consuming, creating barriers for healthcare providers unfamiliar with this evolving field. Regulatory challenges and the lack of standardized guidelines for pharmacogenomic testing can also contribute to inconsistencies in adoption, limiting the ability to integrate these tests into mainstream clinical practice effectively.

Market Trends of the Global Pharmacogenomics Market

The Global Pharmacogenomics market is witnessing a significant trend characterized by the integration of artificial intelligence to enhance genomic analysis. This strategic incorporation facilitates accelerated genome sequencing, streamlines the identification of therapeutic biomarkers, and optimizes drug response predictions. Companies committed to innovation are leveraging AI models that not only improve diagnostic accuracy but also minimize discovery delays, translating to cost-effective solutions for pharmacogenomic testing. This technological advancement fosters a more practical application of pharmacogenomics in both research and clinical environments, thereby reshaping healthcare delivery and personalizing treatment strategies for patients worldwide.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Technology Assessment
• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Technology Analysis
• Case Studies
• Value Chain Analysis

Global Pharmacogenomics Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Consumables
  • Kits and Reagents
  • Sequencing Kits
  • PCR Kits
  • Microarray Kits
  • Other Kits
• Equipment
  • Instruments
  • Next Generation Sequencing
  • PCR Equipment
  • Microarray Equipment
  • Other Equipment
• Services
  • Clinical Research
  • Drug Discovery
  • Other Services

Global Pharmacogenomics Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Next-Generation Sequencing (NGS)
• Polymerase Chain Reaction (PCR)
• Microarray
• Gel Electrophoresis
• Mass Spectrometry
• Others

Global Pharmacogenomics Market Size by Disease Area & CAGR (2026-2033)

• Market Overview
• Oncology
• Neurological Diseases
• Cardiovascular Diseases
• Infectious Diseases
• Mental Health
• Other Disease Areas

Global Pharmacogenomics Market Size by Sample Type & CAGR (2026-2033)

• Market Overview
• Blood
• Saliva / Buccal Swab
• Tissue
• Others

Global Pharmacogenomics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Drug Discovery & Development
• Clinical Diagnostics
• Personalized Medicine
• Others

Global Pharmacogenomics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals and Clinics
• Academic and Research Institutions
• Pharmaceutical Companies
• Contract Research Organizations
• Other End Users

Global Pharmacogenomics Market Size & CAGR (2026-2033)

• North America (Product Type, Technology, Disease Area, Sample Type, Application, End User)
  • US
  • Canada
• Europe (Product Type, Technology, Disease Area, Sample Type, Application, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Technology, Disease Area, Sample Type, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Technology, Disease Area, Sample Type, Application, End User)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Technology, Disease Area, Sample Type, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• 23andMe
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genomic Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Foundation Medicine
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invitae
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Precision Medicine Group
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Caris Life Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Guardant Health
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tempus
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioReference Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ArcherDX
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GRAIL
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Progenity
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asuragen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Qiagen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genetron Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genetic Technologies
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenomOncology
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations